About HIFU Prostate
The HIFU Prostate Website
The HIFU Prostate website was created to provide useful information about prostate cancer for patients, with a particular focus on HIFU treatment.
The information presented on this website is intended for the general public as well as for physicians seeking information about prostate cancer or HIFU technology.
The content available on this website cannot replace a professional medical diagnosis or the discussions you may have with your physician or urologist.
Funding
HIFU Prostate is entirely funded by the company EDAP TMS.
The company is located at 4, rue du Dauphiné, 69120 Vaulx-en-Velin, France.
Advertising
There is no advertising on the HIFU Prostate website.
The Company
A leader in therapeutic ultrasound and active in the market for over 40 years, EDAP TMS (NASDAQ: EDAP) develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices in urology based on ultrasound technology.
By combining the latest advances in imaging and therapy, EDAP has introduced the Focal One®. In addition to the existing Ablatherm® system, Focal One® is indicated for the treatment of localized prostate cancer.
As a pioneer and key player in extracorporeal shock wave lithotripsy (ESWL), EDAP TMS also delivers the Sonolith®, which uses shock wave technology.
Development Partnerships
EDAP TMS develops its medical devices with the support of the French National Institute of Health and Medical Research (INSERM) and the team at Édouard Herriot Hospital in Lyon, France.
Expert teams from these three organizations have been working together for many years to develop current and future medical devices.
The goal of these technologies is to meet the needs of healthcare professionals while preserving patients’ quality of life as much as possible.